Domestic Pharmaceutical Retail market rises 11 percent in July

In July, the domestic pharmaceutical retail market witnessed a remarkable 11 percent increase. This phenomenon can be referred to as the flu impact. Increased sales of anti-infectives and pain relief suggest a rise in cases of flu and other viral infections.

Augmentin antibiotic led in sales with Rs 72 crore and reflected the trend of the disease. It also became the top-selling brand in the nation for the month.

According to the most recent data from IQVIA, anti-infectives, pain-relief, and gastroenterology medications experienced significant growth rates of 14%, 11%, and 15% in July. In July, the market experienced an 8 per cent increase in its moving annual total (MAT) growth.

The significant rise in sales is due to the high number of cases of flu, viral infections, and vector-borne diseases in June and July caused by the rainy season across the country.

Anti-infectives, such as antibiotics, antifungals, and antivirals, are commonly used to combat bacterial and viral infections. In total, the pharmaceutical retail market, worth approximately Rs 2,22,906 crore, saw a growth of 7 percent in June. Augmentin, a brand under GSK Pharma, a pharmaceutical firm moved up four positions to secure the top spot. In July 2023, it secured the second position with revenues of Rs 70 crore.

The company reported that its main products - Calpol, Augmentin, and T-Bact, experienced a robust increase of 10 percent in the most recent quarter ending on June 30. According to the company, Augmentin, a blend of amoxicillin and clavulanic acid, surpassed its category and increased market share despite being subject to price control.